MannKind Corporation’s $230 Million Notes Offering

Goodwin Procter LLP advised the initial purchasers on the deal.

MannKind Corporation (the “Company”) completed its previously announced private offering (the “Offering”) of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the “Notes”). The Notes were issued pursuant to an indenture, dated March 4, 2021 (the “Indenture”), between the Company and U.S. Bank National Association, as trustee. Pursuant to the purchase agreement between the Company and the initial purchasers of the Notes, the Company granted the initial purchasers an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $30.0 million principal amount of Notes.

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases.

The Initial Purchasers are J.P. Morgan Securities LLC, SVB Leerink LLC, RBC Capital Markets, LLC, BTIG, LLC, H.C. Wainwright & Co., LLC.

Goodwin’s team consisted of Jim Barri (Picture), John Servidio, Maggie Wong, Kim Sebastian De Glossop, Evyn Rabinowitz and Patrick Wilson with assistance from Daniel Karelitz and Garrett Gaughan.

Involved fees earner: James Barri – Goodwin Procter; Kim de Glossop – Goodwin Procter; Garrett Gaughan – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Evyn Rabinowitz – Goodwin Procter; John Servidio – Goodwin Procter; Patrick Wilson – Goodwin Procter; Maggie Wong – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: BTIG, LLC; H.C. Wainwright & Co.; J.P. Morgan Securities LLC; RBC Capital Markets; SVB Leerink LLC;

Author: Martina Bellini